European journal of breast health最新文献

{"title":"Techniques for Retaining the Inframammary Fold in Implant-Based Reconstructive Breast Surgery.","authors":"Artem Mishin, Alla Kartasheva, Viktor Okhotin, Igor Ganshin","doi":"10.4274/ejbh.galenos.2025.2025-2-1","DOIUrl":"10.4274/ejbh.galenos.2025.2025-2-1","url":null,"abstract":"<p><p>Both reconstructive and aesthetic implant-based breast surgery are associated with the risk of damage or destruction of the inframammary fold (IMF). Such surgical complications lead to implant disposition and disruption of the natural shape of the breast. Various techniques are used to restore the IMF or prevent its damage, such as tissue rearrangement, sutures, capsular flaps, the use of biological matrices or synthetic meshes. In this review, all current methods of retaining the IMF and the frequency of complications reported over the past ten years are reviewed.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"190-199"},"PeriodicalIF":1.3,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bayesian Model Prediction for Breast Cancer Survival: A Retrospective Analysis.","authors":"Islam Bani Mohammad, Muayyad M Ahmad","doi":"10.4274/ejbh.galenos.2025.2025-2-14","DOIUrl":"10.4274/ejbh.galenos.2025.2025-2-14","url":null,"abstract":"<p><strong>Objective: </strong>Over the recent years, machine learning (ML) models have been increasingly used in predicting breast cancer survival because of improvements in ML algorithms. However, cancer researchers still face a significant challenge in accurately predicting breast cancer patients' survival rates. The purpose was to predict breast cancer survival using a Bayesian network.</p><p><strong>Materials and methods: </strong>This retrospective study included 2,995 patients diagnosed with breast cancer and subsequently hospitalized between January 1, 2012, and December 30, 2024. SPSS Modeler version 18.0 was used to build prediction models. The data were randomly split into a training set (2,097 cases, 70%) and a test set (898 cases, 30%) for developing the Bayesian network model and predicting the overall survival of patients diagnosed with breast cancer. The model included demographic variables (age, marital status, and governorate), laboratory/clinical variables (hemoglobin level, white blood cell count, presence of hypertension, and diabetes mellitus) and the outcome variable, patient survival status (binary value: survived/died). The discriminative ability of models was evaluated by accuracy and the area under the curve (AUC) in terms of superior predictive performance for breast cancer outcomes.</p><p><strong>Results: </strong>The Bayesian model exhibited the best discriminatory performance among the nine models, with an AUC of 0.859 and the highest accuracy of 96.661%. In the context of feature importance, white blood cell value at the time of diagnosis was the most important feature for predicting the survival of breast cancer. Patients who had below-normal hemoglobin and above-normal white blood count values had a higher death probability than patients who had normal white blood count and hemoglobin values. The presence of hypertension and diabetes mellitus in patients with breast cancer led to a reduced survival probability.</p><p><strong>Conclusion: </strong>The Bayesian model outperformed the other models in predicting the survival probability of breast cancer. Routine laboratory testing and demographic data can be included in a ML model to predict breast cancer survival. Accurate prediction of breast cancer survival is vital for clinical decision-making.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"255-264"},"PeriodicalIF":1.3,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bilateral Gestational Gigantomastia Complicating Pregnancy: A Challenging Case Refractory to Conservative Management.","authors":"Sathasivam Pravanan, Lakindu Grero, Widuranga Wijerathna, Kasun Ranaweera, Jeewantha Senavirathna, S H Rukman Sanjeewa, Kanchana Wijesinghe","doi":"10.4274/ejbh.galenos.2025.2025-4-4","DOIUrl":"10.4274/ejbh.galenos.2025.2025-4-4","url":null,"abstract":"<p><p>Gestational gigantomastia (GG) is a rare condition characterized by excessive and rapid breast enlargement during pregnancy, resulting in significant physical discomfort, functional limitations, and significant psychological impact. We present a case of a 33-year-old multiparous woman in her third pregnancy, who developed severe bilateral GG by 16 weeks of gestation. Despite initial conservative management, including analgesia and pharmacological (bromocriptine) therapy, the condition worsened causing functional impairment and recurrent mastitis requiring repeated hospital admissions. The pregnancy was electively induced due to physical limitations at 35 weeks of gestation; however, the labour was complicated by obstruction, necessitating an emergency Cesarean section. Postpartum the patient developed severe lactational mastitis complicated by sepsis necessitating intensive care unit admission. After recovery and cessation of breastfeeding, she elected to undergo Wise-pattern bilateral reduction mammoplasty with free nipple-areolar complex grafting four months into her postpartum period. The procedure provided substantial functional relief and a favorable esthetic outcome. This case highlights the potential complexity of managing GG and the need for individualized care. Although conservative treatments may offer temporary relief, surgical intervention is often necessary in severe cases.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"98-101"},"PeriodicalIF":1.7,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12740280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144176218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated Hydatid Cyst of the Breast: A Rare Pseudotumor of the Breast.","authors":"Badra Bannour, Mariem Romdhani, Dorra Chiba, Imen Bannour, Atef Ben Abdelkader, Moncef Mokni, Sassi Boughizane","doi":"10.4274/ejbh.galenos.2025.2024-12-10","DOIUrl":"10.4274/ejbh.galenos.2025.2024-12-10","url":null,"abstract":"<p><p>Although rare, a hydatid cyst of the breast represents a mammary pseudotumor. We present the case of a 49-year-old woman with no significant medical history, who was diagnosed with an isolated hydatid cyst of the breast confirmed by histopathological examination. This patient consulted for breast asymmetry and a feeling of heaviness in the left breast, with no clinical signs of systemic hydatidosis. The diagnosis was suggested by echo-mammography and confirmed postoperatively by histopathological examination. Although rarely reported, primary hydatid cyst of the breast can cause symptoms that mimic neoplasia. Surgical excision alone proved effective in treating this type of breast cyst.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"182-185"},"PeriodicalIF":1.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Age, Stage and Biology of Breast Cancer Presentations at A Private Breast Unit in Johannesburg Before and During The COVID-19 Pandemic.","authors":"Nazreen Kara, Dominic da Costa, Ella Dougherty, Amina Mahomed, Cassandra Mbanje, Carol-Ann Benn, Dominic van Loggerenberg","doi":"10.4274/ejbh.galenos.2025.2024-12-2","DOIUrl":"10.4274/ejbh.galenos.2025.2024-12-2","url":null,"abstract":"<p><strong>Objective: </strong>Prior to the 2020 Coronavirus disease 2019 (COVID-19) pandemic, breast cancer (BC) was already a major healthcare concern globally, including in South Africa (SA). The pandemic forced adjustments in BC management and may have also impacted BC presentation characteristics due to social behavior changes. The aim of this study was to describe BC presentations before and during the COVID-19 pandemic at a single facility in SA.</p><p><strong>Materials and methods: </strong>A retrospective record review was conducted to compare BC presentations before and during the COVID-19 pandemic. The \"before\" period spanned 11 January 2019 to 31 March 2020 and the \"during\" period spanned 1 April 2020 to 20 December 2021. The variables analysed included patient age, BC stage at presentation, and tumor biology.</p><p><strong>Results: </strong>A total of 731 patients were seen in the \"before\" period, and 636 in the \"during\" period. While there was a significant (<i>p</i><0.0001) decrease in the mean number of patients who presented to the unit per month during the pandemic, no significant differences were observed in age, BC stage at presentation, or tumor biology between the two study periods.</p><p><strong>Conclusion: </strong>Despite a significant reduction in new BC cases during the COVID-19 pandemic in SA, patient age, BC stage, and tumor biology remained unchanged. The rapid implementation of digital tools for healthcare management is likely to have played an important role in maintaining patient access to care.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"132-136"},"PeriodicalIF":1.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143569066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life and Age-Related Predictor Symptoms in Breast Cancer Survivors Undergoing Hormone Therapy: A Study from the Northern Region of Morocco.","authors":"Fadoua El Battioui, Abdelouahid Louazi, Noura Boukil, Zohra Ben Allal, Rajae Alloudane, Said Barrijal","doi":"10.4274/ejbh.galenos.2025.2024-5-4","DOIUrl":"10.4274/ejbh.galenos.2025.2024-5-4","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to assess the health-related quality of life (HRQoL) of breast cancer (BC) survivors during adjuvant hormone therapy (AHT) as a function of age and to identify predictor symptoms.</p><p><strong>Materials and methods: </strong>The study was based on a cross-sectional survey of 216 BC survivors undergoing AHT, in the Northern Region of Morocco. HRQoL was assessed using a validated HRQoL questionnaire, the Functional Assessment of Cancer Treatment (FACT-ES). Multiple linear regression analysis was used to identify predictor symptoms for the subscales of the FACT-ES.</p><p><strong>Results: </strong>Younger women (<45 years) had lower scores on the emotional well-being subscale (<i>p</i> = 0.021). Irritability (b: -0.786; p = 0.001) and mood swings (b: -0.835; <i>p</i> = 0.031) were the strongest negative predictors of emotional quality of life. In both age groups, items related to social support had a positive effect on survivors' social HRQoL (<i>p</i><0.05).</p><p><strong>Conclusion: </strong>BC survivors' HRQoL during AHT differed by age group. Emotional problems negatively influenced HRQoL in younger women. Knowledge of the symptoms that predict HRQoL in BC survivors may help clinicians develop personalized interventions.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"115-121"},"PeriodicalIF":1.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143443052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-Related Quality of Life in Breast Cancer Patients during Chemotherapy: A Cross-Sectional Study Using the EORTC QLQ-C30 and BR45.","authors":"Ali Haider Asad, Praschaya Kaushik, Jehath Syed, Janhavi P Kherodkar, Sanskruti R Katkar, Aman Chaudhary, Asavari Raut","doi":"10.4274/ejbh.galenos.2025.2024-12-1","DOIUrl":"10.4274/ejbh.galenos.2025.2024-12-1","url":null,"abstract":"<p><strong>Objective: </strong>To assess health-related quality of life (HRQoL) using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Breast Cancer (EORTC QLQ-BR45) in conjunction with the Core questionnaire (EORTC QLQ-C30) in breast cancer patients receiving chemotherapy.</p><p><strong>Materials and methods: </strong>This prospective, cross-sectional study was conducted in the oncology department of a tertiary care hospital for six months. Patients aged ≥18 years, diagnosed with breast cancer, and who had received at least three chemotherapy cycles were included in the study. The EORTC (QLQ-BR45 and QLQ-C30) questionnaires were used to assess HRQoL at chemotherapy cycle 3 (C3) and at C6 and C9. Data were analyzed using the Mann-Whitney U and Friedman tests for significance (<i>p</i><0.05).</p><p><strong>Results: </strong>The study showed improved global health status (C3:37.29%, C6:42.37%, C9:50%), high cognitive functioning (C3:89.83%, C6:91.53%, C9:96.55%), but decreasing emotional functioning (C3:66.10%, C6:49.15%, C9:36.21%). Symptom burden peaked in the sixth cycle but diminished over time with a trend towards fatigue (C3:64.41%, C6:67.80%, C9:37.93%), dyspnea (C3:54.24%, C6:55.93%, C9:32.76%), and pain (C3:42.37%, C6:52.54%, C9:34.48%). The study indicated satisfaction with body image (C3:61.02%, C6:67.80%, C9:67.24%) but decreased sexual functioning (C3:40.68%, C6:44.07%, C9:46.55%). Distress related to hair loss (<i>p</i> = 0.0001) increased over time.</p><p><strong>Conclusion: </strong>There was increased symptom burden at C6, underscoring the need for early interventions. We observed severe symptoms in elderly. However, lack of comorbidities and metastasis improved the emotional wellbeing in patients. These findings accentuate the importance of personalized and holistic care approaches in oncology.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"162-172"},"PeriodicalIF":1.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143627183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organized Breast Cancer Screening in Diabetic Women: A Prospective Study Among 100,000 Women from the Grand-Est Region (France), from 2020 to 2022.","authors":"Maurine Parrent, Elisa Filiu, Tolga Ozmen, Odile Blanchard, Ouarda Pereira, Carole Mathelin","doi":"10.4274/ejbh.galenos.2025.2025-1-4","DOIUrl":"10.4274/ejbh.galenos.2025.2025-1-4","url":null,"abstract":"<p><strong>Objective: </strong>The risk of breast cancer in type 2 diabetic women is increased by 10-20%. Diabetic women have a higher risk of being diagnosed with advanced breast cancer and having complications with its treatments. In France, women aged between 50 and 74 years old are invited to undergo organized breast cancer screening (OBCS). The objective of this study was to evaluate OBCS participation in a large cohort of diabetic women.</p><p><strong>Materials and methods: </strong>Based on data from Social Security reimbursement databases, we studied OBCS participation rate of 50-74 years old diabetic women from the Grand-Est region (France) between 2020 and 2022, according to four age brackets and their geographical areas.</p><p><strong>Results: </strong>In 2020, among the 99,302 diabetic women, 16,340 (16.45%) underwent OBCS versus 24% in the general population. In 2021, among the 100,390 diabetic women, 20,914 (20.83%) underwent OBCS, versus 29% in the general population. In 2022, among the 101,694 diabetic women, 18,576 (18.27%) underwent OBCS, versus 24% in the general population. OBCS participation in 50-54 years old and 70-74 years olds were significantly lower (<i>p</i><0.0001 in 2020; <i>p</i><0.0001 in 2021; <i>p</i><0.0037 in 2022). There was a significant link between OBSC participation and geographical area (<i>p</i><0.0001).</p><p><strong>Conclusion: </strong>The OBCS participation rate in women with type 2 diabetes was significantly lower than the general population, and associated with age and area. These findings suggest a need to inform patients and health care professionals about the higher risk of breast cancer in diabetic women to improve OBCS rates with the proven associated health benefits.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"173-181"},"PeriodicalIF":1.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143652796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Significance and Molecular Classification of Triple Negative Breast Cancer: A Systematic Review.","authors":"Ashok Kumar Dogra, Archana Prakash, Sanjay Gupta, Meenu Gupta","doi":"10.4274/ejbh.galenos.2025.2024-10-2","DOIUrl":"10.4274/ejbh.galenos.2025.2024-10-2","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer defined by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression. Despite accounting for 15-20% of all breast cancer cases, TNBC is associated with poor prognosis and a high likelihood of recurrence and metastasis. Understanding the molecular subtypes of TNBC is important for developing targeted therapies and improving patient outcomes. This systematic review aimed to assess the prognostic significance of molecular subtypes of TNBC and the implications for therapeutic management. A comprehensive literature search was conducted across multiple databases, including PubMed, Scopus, and Web of Science, to identify studies focusing on the molecular classification of TNBC and its prognostic relevance. Studies were included based on specific inclusion criteria, including original research evaluating clinical outcomes and survival data in molecularly classified TNBC cohorts. Data were extracted, synthesized, and analyzed to determine the prognostic implications of different TNBC subtypes. The review identified several distinct molecular subtypes of TNBC, including basal-like, mesenchymal, immune-modulatory, and luminal androgen receptor (LAR) subtypes. Basal-like TNBC was associated with poor prognosis and high rates of recurrence, while immune-modulatory TNBC exhibited better survival outcomes, particularly in patients with high levels of tumor-infiltrating lymphocytes. Mesenchymal and LAR subtypes exhibited diverse clinical behavior and varying therapeutic responses. Furthermore, key prognostic biomarkers, such as <i>BRCA1/2</i> mutations and programmed death-ligand 1 expression, were highlighted which have therapeutic implications. Molecular classification of TNBC provides valuable prognostic information and guides therapeutic strategies. Integrating molecular subtyping into clinical decision-making will be essential for the development of personalized treatments and improved outcomes for TNBC patients. However, further research is needed to refine classification systems and address existing therapeutic gaps in TNBC management.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"101-114"},"PeriodicalIF":1.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143545235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound Imaging and Guidance for Tamoxifen-Associated Achilles Tendinopathy.","authors":"Berkay Yalçınkaya, Ahmet Furkan Çolak, Murat Kara, Levent Özçakar","doi":"10.4274/ejbh.galenos.2025.2024-12-5","DOIUrl":"10.4274/ejbh.galenos.2025.2024-12-5","url":null,"abstract":"","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":" ","pages":"188-189"},"PeriodicalIF":1.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}